Literature DB >> 22733240

[Assessment of pruritus - current standards and implications for clinical practice : consensus paper of the Action Group Pruritus Parameter of the International Working Group on Pruritus Research (AGP)].

S Ständer1, C Blome, B Breil, P Bruland, U Darsow, M Dugas, A Evers, F Fritz, M Metz, N Q Phan, U Raap, A Reich, G Schneider, S Steinke, J Szepietowski, E Weisshaar, M Augustin.   

Abstract

With a prevalence of 20%, chronic pruritus is a symptom of many diseases with major impact on healthcare costs. The lack of specific therapeutic measures makes the development of new drugs and their testing in clinical trials urgent. It is not possible to measure pruritus in an objective way. For these reasons, it is necessary to have a series of standardized measures to characterize pruritus in a reliable way. Intensity scales such as the visual analog scale (VAS) are most frequently used to document the course of the symptoms. However, for assessing pruritus intensity, VAS is not an optimal instrument, although it cannot be dispensed with. The VAS should be combined with other scales in clinical studies in order to internally test the consistency of data. Other instruments for assessing intensity and course of pruritus are in the process of development. Presently scratch activity and scratch-associated lesions can be documented in a descriptive fashion. There are some studies that have employed devices to document scratch activity; however, methodological studies are not yet available. The patient-benefit index is an indispensable tool in clinical trials. A questionnaire for gathering data on the history and some pruritus-specific parameters has been developed and published. Questionnaires on patient quality of life, anxiety and depression are helpful in obtaining data on other cost-relevant parameters. A questionnaire on the quality of life, for instance, can provide important help in the assessment of the burden of the disease. The results of these questionnaires can be correlated with data on pruritus intensity scales. The relevant questionnaires have been partially digitalized so that they are available immediately as part of patient care. Additional methodological developments and studies are required in order to define a robust set of instruments for measuring pruritus in daily practice and in clinical studies.

Entities:  

Mesh:

Year:  2012        PMID: 22733240     DOI: 10.1007/s00105-011-2318-3

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  38 in total

Review 1.  [Diagnostic and therapeutic procedures in chronic pruritus].

Authors:  Sonja Ständer; Markus Streit; Ulf Darsow; Volker Niemeier; Maria Vogelgsang; Hartmut Ständer; Uwe Gieler; Harald Gollnick; Dieter Metze; Elke Weisshaar
Journal:  J Dtsch Dermatol Ges       Date:  2006-04       Impact factor: 5.584

2.  Effectiveness of a multidisciplinary itch-coping training programme in adults with atopic dermatitis.

Authors:  Andrea W M Evers; Piet Duller; Elke M G J de Jong; Marisol E Otero; Christianne M Verhaak; Pieter G M van der Valk; Peter C M van de Kerkhof; Floris W Kraaimaat
Journal:  Acta Derm Venereol       Date:  2009       Impact factor: 4.437

3.  A pilot quality-of-life instrument for pruritus.

Authors:  Nisha S Desai; Gabriele B Poindexter; Yvette Miller Monthrope; Sandra E Bendeck; Robert A Swerlick; Suephy C Chen
Journal:  J Am Acad Dermatol       Date:  2008-06-11       Impact factor: 11.527

4.  The 5-D itch scale: a new measure of pruritus.

Authors:  S Elman; L S Hynan; V Gabriel; M J Mayo
Journal:  Br J Dermatol       Date:  2009-12-01       Impact factor: 9.302

5.  Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use.

Authors:  A Y Finlay; G K Khan
Journal:  Clin Exp Dermatol       Date:  1994-05       Impact factor: 3.470

6.  Pruritus as a leading symptom: clinical characteristics and quality of life in German and Ugandan patients.

Authors:  E Weisshaar; C Apfelbacher; G Jäger; E Zimmermann; T Bruckner; T L Diepgen; H Gollnick
Journal:  Br J Dermatol       Date:  2006-11       Impact factor: 9.302

7.  Psychiatric morbidity in dermatological outpatients: an issue to be recognized.

Authors:  A Picardi; D Abeni; C F Melchi; P Puddu; P Pasquini
Journal:  Br J Dermatol       Date:  2000-11       Impact factor: 9.302

8.  A longitudinal study of uremic pruritus in hemodialysis patients.

Authors:  Vandana S Mathur; Jill Lindberg; Michael Germain; Geoffrey Block; James Tumlin; Mark Smith; Mandeep Grewal; Dawn McGuire
Journal:  Clin J Am Soc Nephrol       Date:  2010-06-17       Impact factor: 8.237

9.  The Impact of Chronic Skin Disease on Daily Life (ISDL): a generic and dermatology-specific health instrument.

Authors:  A W M Evers; P Duller; P C M van de Kerkhof; P G M van der Valk; E M G J de Jong; M J P Gerritsen; E Otero; E W M Verhoeven; C M Verhaak; F W Kraaimaat
Journal:  Br J Dermatol       Date:  2007-11-10       Impact factor: 9.302

10.  Recommendations for assessing patient-reported outcomes and health-related quality of life in clinical trials on allergy: a GA(2)LEN taskforce position paper.

Authors:  I Baiardini; P J Bousquet; Z Brzoza; G W Canonica; E Compalati; A Fiocchi; W Fokkens; R G van Wijk; S La Grutta; C Lombardi; M Maurer; A M Pinto; E Ridolo; G E Senna; I Terreehorst; A Todo Bom; J Bousquet; T Zuberbier; F Braido
Journal:  Allergy       Date:  2009-11-20       Impact factor: 13.146

View more
  3 in total

Review 1.  [Chronic pruritus : Care in daily practice].

Authors:  S Ständer; H F Ständer; S Steinke; P Bruland; M Dugas; M Augustin
Journal:  Hautarzt       Date:  2016-08       Impact factor: 0.751

2.  Analysis of 325 Patients with Chronic Nodular Prurigo: Clinics, Burden of Disease and Course of Treatment.

Authors:  Sonja Gründel; Manuel P Pereira; Michael Storck; Nani Osada; Gudrun Schneider; Sonja Ständer; Claudia Zeidler
Journal:  Acta Derm Venereol       Date:  2020-09-30       Impact factor: 3.875

3.  Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial.

Authors:  Ruth Bolier; Elsemieke S de Vries; Albert Parés; Jeltje Helder; E Marleen Kemper; Koos Zwinderman; Ronald P Oude Elferink; Ulrich Beuers
Journal:  Trials       Date:  2017-05-23       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.